Clinical Trial

NXC-201 (formerly HBI0101) Multiple Myeloma

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated March 14, 2025 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.
Summary
It is a phase one study with dose escalation and safety CART in BCMA- Expressing Multiple Myeloma and AL amyloidosis Patients
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-01-21; most recent amendment 2025-03-12.
Status change: Recruiting → Active, Not Recruiting 2025-03-12
Trial Details
NCT Number NCT04720313
Lead Sponsor Hadassah Medical Organization
Collaborators: Nexcella Inc.
Conditions Dose Escalation and Safety
Enrollment 160 participants
Start Date 2021-01-01
Primary Completion 2026-01 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-14